- Home
- STTK vs IPHA Comparison
STTK vs IPHA Comparison
Compare STTK & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- IPHA
- Stock Information
- Founded
- STTK 2016
- IPHA 1999
- Country
- STTK United States
- IPHA France
- Employees
- STTK N/A
- IPHA N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- IPHA Health Care
- Exchange
- STTK Nasdaq
- IPHA Nasdaq
- Market Cap
- STTK 173.6M
- IPHA 191.0M
- IPO Year
- STTK 2020
- IPHA 2019
- Fundamental
- Price
- STTK $3.74
- IPHA $2.28
- Analyst Decision
- STTK Strong Buy
- IPHA Strong Buy
- Analyst Count
- STTK 3
- IPHA 1
- Target Price
- STTK $10.67
- IPHA $11.50
- AVG Volume (30 Days)
- STTK 123.8K
- IPHA 5.5K
- Earning Date
- STTK 11-07-2024
- IPHA 09-12-2024
- Dividend Yield
- STTK N/A
- IPHA N/A
- EPS Growth
- STTK N/A
- IPHA N/A
- EPS
- STTK N/A
- IPHA N/A
- Revenue
- STTK $4,123,999.00
- IPHA $36,202,722.00
- Revenue This Year
- STTK $164.45
- IPHA N/A
- Revenue Next Year
- STTK N/A
- IPHA $105.84
- P/E Ratio
- STTK N/A
- IPHA N/A
- Revenue Growth
- STTK 380.09
- IPHA 6.88
- 52 Week Low
- STTK $1.33
- IPHA $1.81
- 52 Week High
- STTK $11.76
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- STTK 53.41
- IPHA 50.55
- Support Level
- STTK $3.63
- IPHA $2.27
- Resistance Level
- STTK $3.94
- IPHA $2.41
- Average True Range (ATR)
- STTK 0.22
- IPHA 0.11
- MACD
- STTK 0.06
- IPHA -0.00
- Stochastic Oscillator
- STTK 64.91
- IPHA 52.94
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.